Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results.

Abstract

Liposarcoma is one of the most common adult soft tissue sarcomas and consists of three histologic subtypes (well and dedifferentiated, myxoid/round cell, and pleomorphic). Surgery is the mainstay of treatment for localized disease; however for unresectable or metastatic disease, effective treatment options are currently limited. In the past decade, a better understanding of the distinct genetic and molecular aberrations for each of the three histologic subtypes has led to the development of several novel systemic therapies. Data from phase I and early phase II clinical trials have been reported. Despite challenges with conducting clinical trials in liposarcoma, preliminary results for several of these novel, biology-driven therapies are encouraging.

• Authors: William W Tseng, Neeta Somaiah, Alexander J Lazar, Dina C Lev, Raphael E Pollock
• Journal: Cancers (Cancers (Basel)) Vol. 5 Issue 2 Pg. 529-49 (May 10 2013) ISSN: 2072-6694 [Print] Switzerland
• PMID: 24216990 (Publication Type: Journal Article)